Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.46 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.46 |
| ▸ | STRADA | Q7RTN6 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4382362 | 0.90 | MAPK14 (0.46) | ALDH1A1LMNASMN1; SMN2HSD17B10KDM4E | |
| SCHEMBL4509497 | 0.86 | ALDH1A1 (0.57) | ALDH1A1LMNASMN1; SMN2HSD17B10KDM4E | |
| SCHEMBL12798301 | 0.86 | MAPK14 (0.44) | ALDH1A1SMN1; SMN2TP53MAPK14ROCK2 | |
| SCHEMBL2706985 | 0.86 | ALDH1A1 (0.53) | ALDH1A1HSD17B10MEN1TP53ALOX15 | |
| SCHEMBL2706592 | 0.85 | MAPK14 (0.57) | ALDH1A1MAPK14ROCK2MAPK12MAPK11 | |
| SCHEMBL6504567 | 0.83 | ALDH1A1 (0.50) | ALDH1A1LMNASMN1; SMN2HSD17B10KDM4E | |
| SCHEMBL12798413 | 0.82 | MAPK14 (0.45) | ALDH1A1TP53MAPTHPGDHTT | |
| SCHEMBL4387425 | 0.82 | ALDH1A1 (0.43) | ALDH1A1LMNASMN1; SMN2HSD17B10KDM4E | |
| SCHEMBL2706645 | 0.81 | ALDH1A1 (0.60) | ALDH1A1LMNASMN1; SMN2HSD17B10KDM4E | |
| SCHEMBL4390396 | 0.80 | ALDH1A1 (0.50) | ALDH1A1LMNAMAPK14ROCK2MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080177077-A1 | PROCESSES FOR THE PREPARATION OF 3-(4-(2,4-DIFLUOROBENZYLOXY)-3-BROMO-6-METHYL-2-OXOPYRIDIN-1(2H)-YL)-N,4-DIMETHYLBENZAMIDE | PFIZER, INC. | 2008-07-24 | — | — | US | claimed |
| EP-2102161-B1 | Processes for the preparation of 3-(4-(2,4-difluorobenzyloxy)-3-bromo-6-methyl- 2-oxopyridin-1(2H)-yl)-N,4-dimethylbenzamide | PFIZER PROD INC (US) | 2012-05-02 | — | — | EP | disclosed |
| EP-2102161-B1 | Processes for the preparation of 3-(4-(2,4-difluorobenzyloxy)-3-bromo-6-methyl- 2-oxopyridin-1(2H)-yl)-N,4-dimethylbenzamide | PFIZER PROD INC (US) | 2012-05-02 | — | — | EP | disclosed |
| US-7906536-B2 | Halogenation of methyl 3-(4-hydroxy-6-methyl-2-oxopyridin-1(2H)-yl)-4-methylbenzoate or derivative; reacting with benzyl halide in solvent and base; chemical intermediates of 4-hydroxy-6-methylpyranone and methyl-3-amino-4-methyl benzoate; amidation, etherification, esterification; p38 kinase inhibitor | PFIZER INC (US) | 2011-03-15 | — | — | US | disclosed |
| US-7906536-B2 | Halogenation of methyl 3-(4-hydroxy-6-methyl-2-oxopyridin-1(2H)-yl)-4-methylbenzoate or derivative; reacting with benzyl halide in solvent and base; chemical intermediates of 4-hydroxy-6-methylpyranone and methyl-3-amino-4-methyl benzoate; amidation, etherification, esterification; p38 kinase inhibitor | PFIZER INC (US) | 2011-03-15 | — | — | US | disclosed |
| US-7906536-B2 | Halogenation of methyl 3-(4-hydroxy-6-methyl-2-oxopyridin-1(2H)-yl)-4-methylbenzoate or derivative; reacting with benzyl halide in solvent and base; chemical intermediates of 4-hydroxy-6-methylpyranone and methyl-3-amino-4-methyl benzoate; amidation, etherification, esterification; p38 kinase inhibitor | PFIZER INC (US) | 2011-03-15 | — | — | US | disclosed |
| US-20090270350-A1 | Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives | PFIZER INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090270350-A1 | Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives | PFIZER INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090270350-A1 | Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives | PFIZER INC. | 2009-10-29 | — | — | US | disclosed |
| EP-2102161-A2 | PROCESSES FOR THE PREPARATION OF 3-(4-(2,4-DIFLUOROBENZYLOXY)-3-BROMO-6-METHYL-2-OXOPYRIDIN-1(2H)-YL)-N,4-DIMETHYLBENZAMIDE | Pfizer Products Incorporated (US) | 2009-09-23 | — | — | EP | disclosed |
| JP-2008231090-A | PROCESS FOR PREPARING 3-(4-(2,4-DIFLUOROBENZYLOXY)-3-BROMO-6-METHYL-2-OXOPYRIDINE-1(2H)-YL)-N,4-DIMETHYLBENZAMIDE | PFIZER PROD INC | 2008-10-02 | — | — | JP | disclosed |
| US-20080177077-A1 | PROCESSES FOR THE PREPARATION OF 3-(4-(2,4-DIFLUOROBENZYLOXY)-3-BROMO-6-METHYL-2-OXOPYRIDIN-1(2H)-YL)-N,4-DIMETHYLBENZAMIDE | PFIZER, INC. | 2008-07-24 | — | — | US | disclosed |
| US-20080177077-A1 | PROCESSES FOR THE PREPARATION OF 3-(4-(2,4-DIFLUOROBENZYLOXY)-3-BROMO-6-METHYL-2-OXOPYRIDIN-1(2H)-YL)-N,4-DIMETHYLBENZAMIDE | PFIZER, INC. | 2008-07-24 | — | — | US | disclosed |
| US-20080177077-A1 | PROCESSES FOR THE PREPARATION OF 3-(4-(2,4-DIFLUOROBENZYLOXY)-3-BROMO-6-METHYL-2-OXOPYRIDIN-1(2H)-YL)-N,4-DIMETHYLBENZAMIDE | PFIZER, INC. | 2008-07-24 | — | — | US | disclosed |
| WO-2008072079-A2 | PROCESSES FOR THE PREPARATION OF 3-(4-(2,4-DIFLUOROBENZYLOXY)-3-BROMO-6-METHYL-2-OXOPYRIDIN-1(2H)-YL)-N,4-DIMETHYLBENZAMIDE | PFIZER PRODUCTS INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008072079-A2 | PROCESSES FOR THE PREPARATION OF 3-(4-(2,4-DIFLUOROBENZYLOXY)-3-BROMO-6-METHYL-2-OXOPYRIDIN-1(2H)-YL)-N,4-DIMETHYLBENZAMIDE | PFIZER PRODUCTS INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-2007091176-A1 | PYRIDINONE PYRAZOLE UREA AND PYRIMIDINONE PYRAZOLE UREA DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270350-A1 | Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives | PDXK, UMPS, CDK2 | ALDH1A1 1197/4885LMNA 2954/4885SMN1; SMN2 4091/4885 |
| US-20080177077-A1 | PROCESSES FOR THE PREPARATION OF 3-(4-(2,4-DIFLUOROBENZYLOXY)-3-BROMO-6-METHYL-2-OXOPYRIDIN-1(2H)-YL)-N,4-DIMETHYLBENZAMIDE | CYP4X1, CYP4B1, KDM4B | ALDH1A1 1589/4885LMNA 1184/4885SMN1; SMN2 1719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.